Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdCLD-CoV19-1 Immunogenicity and Safety in Healthy Adults
NCT05520970Phase 2Terminated
- Sponsor
- Cellid Co., Ltd.
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of AdCLD-CoV19-1 OMI in coronavirus disease 2019 (COVID-19), sponsored by Cellid Co., Ltd.. Started Aug 2022; status: terminated.
02
Drugs
AdCLD-CoV19-1 OMI
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05520970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05520970.